<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463044</url>
  </required_header>
  <id_info>
    <org_study_id>MOT-C-104</org_study_id>
    <nct_id>NCT03463044</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Randomised, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Ascending, Single, Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotrem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inotrem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single center, randomized, placebo-controlled study with a sequential i.v. dose
      escalation cohorts design, to assess safety, tolerability and pharmacokinetics of MOTREM
      (nangibotide) in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">August 25, 2016</completion_date>
  <primary_completion_date type="Actual">August 25, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: Number of subjects with at least one adverse event</measure>
    <time_frame>28 days</time_frame>
    <description>Number of subjects with at least one adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Maximum Plasma Concentration)</measure>
    <time_frame>8 hours</time_frame>
    <description>Maximum Plasma Concentration [Cmax]</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nangibotide</intervention_name>
    <description>Continous i.v. infusion</description>
    <arm_group_label>MOTREM 1</arm_group_label>
    <arm_group_label>MOTREM 2</arm_group_label>
    <arm_group_label>MOTREM 3</arm_group_label>
    <arm_group_label>MOTREM 4</arm_group_label>
    <arm_group_label>MOTREM 5</arm_group_label>
    <arm_group_label>MOTREM 6</arm_group_label>
    <arm_group_label>MOTREM 7</arm_group_label>
    <arm_group_label>MOTREM 8</arm_group_label>
    <other_name>LR12</other_name>
    <other_name>MOTREM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male

          -  ≥18 to ≤45 years old

          -  Body mass index (BMI) between 18-30 kg/m² inclusive

          -  Written informed consent to participate.

        Main Exclusion Criteria:

          -  Any clinically relevant acute or chronic diseases

          -  Any history of drug or alcohol abuse

          -  Any History of clinical significant disease as determined by medical history, physical
             examination or other evaluations.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Cuvier</last_name>
    <role>Study Director</role>
    <affiliation>Inotrem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd.</name>
      <address>
        <city>Croydon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

